InvestorsHub Logo
Followers 34
Posts 3030
Boards Moderated 0
Alias Born 02/27/2016

Re: None

Tuesday, 04/09/2019 8:03:18 AM

Tuesday, April 09, 2019 8:03:18 AM

Post# of 469765
Value-Creating Catalysts – Clinical updates from Phase 2 Parkinson’s disease dementia study, Phase 2b/3 Alzheimer’s disease and Phase 2 Rett syndrome studies anticipated in 2019. Clinical data publications and additional indications to be announced in 2019.

So many to choose from. What could it be?

Anxiety disorders, mood disorders, psychotic disorders, etc.

Come on Merck, let's do this partnership for these other indications.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News